Stock Ratings / Health Care / NSPR / forecast

PLRZ (42) PMI (61) RVP (33) MODD (36) ⌘ Pro Terminal →

InspireMD Inc. (NSPR) 12-Month Stock Forecast & Price Target Cone

Q: What is NSPR's 12-month stock price target?

InspireMD Inc. (NSPR) carries a 12-month consensus base price target of $0.41 (-8.9% from $0.45), with a bull-case target of $2.52 and a bear-case floor of $0.32.

Q: Is NSPR stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NSPR D- (Sell — SELL) with an RQD Confidence score of 38/100.

$0.45 -3.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.45

InspireMD Inc. (NSPR) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $21.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.45 (-0.83%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NSPR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY NSPR SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.52-11.5% Next Q

Q2 (-2Q)

Grade D$0.46-2.2% Next Q

Q3 (-1Q)

Grade D$0.45+0% Next Q

Current

Grade D-$0.45-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NSPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NSPR currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.66) and Max Pain ($0.47) forces dealer call-delta covering toward $2.52.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NSPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NSPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NSPR Position Size: $10,000

Shares at $0.45: 22222.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.32

$7,111

$-2,889 (-28.9%)

12M Consensus BaseTarget $0.41

$9,111

$-889 (-8.9%)

12M Bull Case BreakoutTarget $2.52

$56,000

+$46,000 (+460.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$0	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$2	69%	B
JP MorganUS Large-Cap Research	SELL	$0	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NSPR)

✓Walkthrough of NSPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NSPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.86%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.44H $0.47L $0.44C $0.45VOL 478.7K

RES: $0.80SUP: $0.42SMA50: $0.66SMA200: $1.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NSPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NSPR Butterfly Map → + Track NSPR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +28.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NSPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NSPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NSPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NSPR)

Health Care Rank #727 of 1016 ⚔️ PLRZ vs NSPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NSPR vs. PLRZ, PMI, RVP, MODD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InspireMD Inc. (NSPR) ranks #727 by composite RQD confidence (38/100, grade D-) and #829 by equity capitalization ($21.0M). Within this direct 5-issuer industry benchmark cohort, NSPR leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NSPR at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NSPR ACTIVE InspireMD Inc.	D-	38/100	—	29.5%	-35.0%	-3.55%	$21.0M	Benchmark Subject
PLRZ Polyrizon Ltd.	D-	42/100	—	—	-25.1%	+4.57%	$21.9M	/plrz-vs-nspr →
PMI Picard Medical Inc.	C-	61/100	—	—	—	+12.17%	$19.9M	/pmi-vs-nspr →
RVP Retractable Technologies Inc.	E	33/100	—	0.1%	-23.3%	-1.15%	$17.3M	/rvp-vs-nspr →
MODD Modular Medical Inc.	D-	36/100	—	—	-35.0%	-9.95%	$16.3M	/modd-vs-nspr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001433607

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InspireMD Inc. (NSPR) reported GAAP revenue of $9.0M (+28.1% vs. FY2024 revenue of $7.0M , and +44.7% cumulative change since FY2023) , GAAP net income of -$48.8M, operating cash flow of -$35.1M, and free cash flow of -$36.8M (-58.0% YoY). On the balance sheet, NSPR closed FY2025 with $69.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.0M	-$48.8M	-$35.1M	-$36.8M	$69.4M	—
FY2024 (FY)	2024-12-31	$7.0M	-$32.0M	-$21.9M	-$23.3M	$46.8M	—
FY2023 (FY)	2023-12-31	$6.2M	-$19.9M	-$16.4M	-$16.4M	—	—

3. NSPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, InspireMD Inc. (NASDAQ: NSPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.45 (-3.55% 1D, market cap $21.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NSPR ranks #727 in composite RQD confidence.

How does NSPR compare to PLRZ and PMI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NSPR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 29.5%, and ROIC of -35.0%. By comparison, PLRZ (Polyrizon Ltd.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -25.1%, cap $21.9M) and PMI (Picard Medical Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $19.9M). Among the 5-stock peer group, NSPR leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NSPR?

Per NSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001433607), InspireMD Inc. generated $9.0M in revenue (+28.1% YoY), -$48.8M in net income, and -$36.8M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NSPR trading relative to its 50-day, 200-day, and 52-week technical levels?

NSPR last traded at $0.45 (-3.55% on volume of 207,120 shares), positioning the stock -31.82% below its 50-day simple moving average ($0.66) and -57.94% below its 200-day simple moving average ($1.07). Across its 52-week range of $0.43 to $2.40, NSPR sits at the 1.0% percentile with a 14-day RSI of 30.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.51).

NSPR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NSPR's 12-month stock price target?

InspireMD Inc. (NSPR) carries a 12-month consensus base price target of $0.41 (-8.9% from $0.45), with a bull-case target of $2.52 and a bear-case floor of $0.32.

Is NSPR stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NSPR D- (Sell — SELL) with an RQD Confidence score of 38/100.

Direct Sub-Reports: NSPR RQD Cockpit NSPR 12M Forecast NSPR Earnings & Move NSPR Dividends & DRIP NSPR Insiders & 13F NSPR Whale Options NSPR Profit Sankey NSPR News & Why